Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Given Consensus Rating of “Hold” by Brokerages

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) has been given a consensus recommendation of “Hold” by the eleven analysts that are covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, four have given a hold rating and six have assigned a buy rating to the company. The average 1-year target price among brokerages that have updated their coverage on the stock in the last year is $40.8889.

Several equities analysts recently weighed in on AGIO shares. Truist Financial reduced their price target on shares of Agios Pharmaceuticals from $39.00 to $36.00 and set a “buy” rating for the company in a research report on Thursday, April 30th. Bank of America reduced their price target on shares of Agios Pharmaceuticals from $41.00 to $40.00 and set a “buy” rating for the company in a research report on Friday, May 29th. JPMorgan Chase & Co. reduced their price target on shares of Agios Pharmaceuticals from $36.00 to $31.00 and set a “neutral” rating for the company in a research report on Thursday, June 11th. Citigroup increased their price target on shares of Agios Pharmaceuticals from $38.00 to $46.00 and gave the company a “buy” rating in a research report on Thursday, March 5th. Finally, Wall Street Zen upgraded shares of Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Sunday, March 22nd.

Agios Pharmaceuticals Price Performance

Shares of AGIO stock opened at $34.16 on Friday. The firm has a 50-day moving average of $29.16 and a 200-day moving average of $28.65. The company has a market cap of $2.03 billion, a P/E ratio of -4.71 and a beta of 0.59. Agios Pharmaceuticals has a one year low of $22.24 and a one year high of $46.00.

Agios Pharmaceuticals (NASDAQ:AGIO) last announced its earnings results on Wednesday, April 29th. The biopharmaceutical company reported ($1.69) EPS for the quarter, beating the consensus estimate of ($1.81) by $0.12. The company had revenue of $20.75 million during the quarter, compared to the consensus estimate of $13.30 million. Agios Pharmaceuticals had a negative net margin of 639.84% and a negative return on equity of 34.11%. The company’s quarterly revenue was up 137.7% on a year-over-year basis. As a group, research analysts expect that Agios Pharmaceuticals will post -6.28 earnings per share for the current fiscal year.

Insider Activity at Agios Pharmaceuticals

In related news, CFO Cecilia Jones sold 3,141 shares of the stock in a transaction dated Thursday, April 2nd. The shares were sold at an average price of $34.71, for a total transaction of $109,024.11. Following the completion of the transaction, the chief financial officer owned 54,998 shares in the company, valued at approximately $1,908,980.58. This represents a 5.40% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Sarah Gheuens sold 2,940 shares of the stock in a transaction dated Thursday, April 2nd. The shares were sold at an average price of $34.71, for a total transaction of $102,047.40. Following the transaction, the insider owned 80,277 shares of the company’s stock, valued at approximately $2,786,414.67. The trade was a 3.53% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 12,623 shares of company stock worth $438,144 in the last ninety days. Corporate insiders own 5.40% of the company’s stock.

Hedge Funds Weigh In On Agios Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. T. Rowe Price Investment Management Inc. bought a new position in Agios Pharmaceuticals during the fourth quarter worth about $25,000. Assetmark Inc. boosted its position in Agios Pharmaceuticals by 37.9% during the fourth quarter. Assetmark Inc. now owns 1,317 shares of the biopharmaceutical company’s stock worth $36,000 after purchasing an additional 362 shares during the period. NewEdge Advisors LLC bought a new position in Agios Pharmaceuticals during the first quarter worth about $40,000. Caitong International Asset Management Co. Ltd bought a new position in Agios Pharmaceuticals during the fourth quarter worth about $49,000. Finally, Quantbot Technologies LP bought a new position in Agios Pharmaceuticals during the third quarter worth about $79,000.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc is a biopharmaceutical company founded in 2008 as a spin-out from research at Dana-Farber Cancer Institute and the Broad Institute. Headquartered in Cambridge, Massachusetts, Agios focuses on understanding and targeting cellular metabolism to develop novel therapies for cancer and rare genetic diseases. The company’s scientific platform integrates genomic discovery, metabolic profiling and precision medicine approaches to identify and advance small-molecule candidates that correct or exploit metabolic dysfunction.

Agios’s lead products are IDH (isocitrate dehydrogenase) inhibitors that target specific cancer mutations.